logo-loader

Teva Pharmaceutical sells women’s health businesses for US$1.38bn

Last updated: 04:27 19 Sep 2017 AEST, First published: 17:27 18 Sep 2017 AEST

deal agreed, handshake
Teva is working through non-core asset sales

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has unveiled two deals which see it dispose of its remaining women’s health products for US$1.38bn.

It is selling contraception, fertility, menopause and osteoporosis drugs to CVC Capital Partners Fund VI for US$703mln in cash, and separately it will sell emergency contraception products to Foundation Consumer Healthcare for US$675mln in cash.

READ: Teva Pharmaceutical names Danish industry veteran Kare Schultz as its new chief executive

Dr Yitzhak Peterburg, Teva interim chief executive, highlighted that the deals follow an earlier US$1.1bn transaction for Paragard and all comes as the company continued its plan of divesting at least US$2bn of non-core assets.

“With these initial divestitures we have exceeded expectations, leveraging the tremendous value we have built within Teva’s specialty business,” Peterburg said in a statement

He added that the deal will “progress our ability to repay term loan debt while also providing a clear path forward for these important products to continue to be available to women throughout the world.”

Shares in Tel Aviv lost 2.79%.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

5 hours, 35 minutes ago